Whenever a drug is used for the first time in the treatment of diseases, the patient is faced with two possible effects. The "placebo effect", i.e. a perceived or real benefit on the part of the patient who believes he is undergoing an effective treatment for his clinical condition even if the medicine does not contain active properties. It is the "nocebo" effect (from the Latin "nocere", to damage), that is, the disturbing shadow of side effects. The detailed information leaflets of medicines, the so-called "leaflets", list a long list of possible negative health effects. These fears, fueled by negative expectations, can trigger the phenomenon. The tools to overcome the problem are correct information and the relationship of trust between doctor and patient.

For a patient suffering from a genetic heart disease, the decision to implant a defibrillator is not an easy one. There are many pros and cons, a lot of information to take into consideration and, although the advice of your doctor is fundamental, the final choice can only be up to the patient.

Reflections on a study appearing in the Journal of the American College of Cardiology which reports the evolution of the incidence, management and prognosis of AC in athletes in France. The complication-free survival rate tripled. In Italy it is necessary to extend CPR training programs and increase the installation of AEDs, also involving middle and high school students and installing AEDs in all workplaces as well as in sports.

The shortage of Nadolol in pharmacies is increasingly worrying doctors and patients and for this reason AICARM APS has decided to contact the director of the Italian Medicines Agency Domenico Di Giorgio to request urgent intervention. In a letter sent on 4 December 2023, President Franco Cecchi, together with the pharmacologist Alessandro Mugelli, asked AIFA to take action to ensure the availability of Nadolol in pharmacies (including by importing it from abroad) and to request its production from the Institute Military Pharmaceutical of Florence.